Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp
Bullboard Posts
User Avatar Image
(27)
•••
Post by pennyDoctoron Oct 28, 2019 7:38pm
288 Views
Post# 30278852

Until now

Until nowI have heard of Canagliflozin , Dapagliflozin,  Emapgliflozin, Ipragliflozin, primarily used in treatment of  type 2 diabetes.

I have just recently searched SGLT and research by Wanbang and they have named SBM TFC039 Wanpagliflozn.  The research must be going very well.  here is the link. https://adisinsight.springer.com/drugs/800032539

SGLT (2) is targetted toward Type 2 diabetes. 

This type of diabetes is chronic in Asia (WHO note below*)and is the most common diabetes.  Still a long road ahead but all looking very promising as competitors in the space have abundant side effects.

*  China spends upwards of RMB 173.4 billion (US $25 billion) a year on the management of diabetes, and 13% of China's medical expenditures are directly caused by diabetes.3

5% potential royalty on even $2.5 Billion US,  is  $1.25 Billion Cash flow without having to produce any drug.
The Wanpagliflozin has the ability to be a block buster drug and the rest of the world will then open up like a flower as drug partners will step up with real dough when Wanbang gets to phase 2 clinical. 

There is a free market report for SGLT https://www.mordorintelligence.com/industry-reports/sglt-2-market

Check it out 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities